As a global authoritative global pharmaceutical news agency, SCRIP recently announced the latest global 100 -compulsory pharmaceutical company rankings in 2011,Pfizer continues to rank at the top of the list,Sanofi ranked second,Merck Pharmaceutical Company passed a large -scale corporate M & A strategy,dramaticly jumped from the 7th place and ranked 3rd,Picking a bronze medal。

 

Pfizer ranks the latest top 100 rankings,Due to the use of large -scale M once again&A (Enterprise M & A) Activity as a means to expand its leading position in the field of prescription drugs。Acquisition Wyeth and King Pharmaceutical Company-completed in the end of 2009 and 2010,Promote the sales of Pfizer's prescription drugs to $ 60 billion,Make a significant gap between Sanofi, who ranked second,。This French pharmaceutical giant found that its dollar sales decreased from last year from 2009 to 2010,Part of the patent due to a large number of popular patents,As a result, a series of small "reinforcement acquisitions" have appeared since 2008,to make the company's business diversified。Sanofi also uses a large amount of cash to look forward,Complete the acquisition of Genzyme in early 2011,This will promote the company's income and biopharmaceutical capabilities。

 

In the 2011 Top 100 Rankings,Merck Pharmaceutical Company dramaticly jumped from the 7th place and ranked 3rd,Picking a bronze medal,This is due to the large -scale M of the company&A strategy; that is, the acquisition of Scheringplough (ScheringPlough) in early 2010。In terms of industrial scale,Entering the top three marks the era of Merhado's entry into the "Renaissance",Before being replaced by Pfizer in the early 2000s,Merhado was the largest prescription pharmaceutical pharmaceutical company。

 

An interesting statement is,After the acquisition of Warner-Lambert, it was acquired by Pfizer in 1999,When the relevant agencies evaluate their respective wealth of the two major pharmaceutical giants in the United States,Pfizer has the right to sell popular blood lipids abnormal therapy (Atropine)。The status of the sales giant has been obtained from Merha East,Pfizer's performance of Super Heetta's performance with heavy mission,Pfizer subsequently acquired Pharmacia (Pharmacia) and the 2009 transaction stake sports betting appstake sports betting appwith Wyeth in 2009,Consolidated its first status。Compared with,Merhadon chose to give up large -scale M during the next ten years&A,During this period, the company lost the opportunity to share with many competitors。Although Merck's income still lags behind Pfizer about $ 20 billion,But the acquisition of SChering-Plough shows the company's intention of reviving。

 

The top 10 pharmaceutical companies rank mostly without changes,But due to M due to Merhado&A positive effect,As a result, some ranking changes。And Abbott jumps in 10th once again shows its strong help for the acquisition of Solvay Pharmaceutical Company。Evaluate the top 10 companies,Pfizer、Sanofer、Merhado、Nova、GlaxoSmot、Roche、Astrikan、Johnson、Lilly and Abbott,The total sales of prescription drugs recorded by these companies are 346 billion US dollars,equivalent to 53%of the total income of the top 100 pharmaceutical companies。Among the elite companies,Swiss company Novartis continues to lead the pace of continuous growth,2009-2010 that the company increased its sales of $ 3 billion in sales,increased by 8.5%compared with last year's growth rate。

 

In recent years,Novartis has reduced the impact of its important patent due to minimum level,By continuously launching new products to obtain a strong market share,Make sales increase quickly。In addition,Novartis uses the diversified structure of large pharmaceutical companies for layout,With its positioning-via Sands-as the second largest generic drug manufacturer in the world,and also strong support in the vaccine market。In addition to the effective continuous growth,Even Nuohua uses M&A to promote its business model,In 2011, I completed the acquisition of Irkang, an ophthalmologist,。

 

GlaxoSmot (GSK)、Roche、Astrikan and Johnson & Johnson have relatively static development compared with last year (Astraikon is the only company that has achieved something),This also makes them still in the top 10。Although the spread of the global H1N1 influenza epidemic in 2010 promoted the sales of GlaxoSmot,Make it gain from influenza therapy medicine,increased sales volume,Wendi Ya's sales decreased steadily,These played an important role in the growth compared with last year。

 

The positive impact of H1N1 influenza on the sales of GlaxoSmithg vaccine (this is due to the results of the government's solution to future prevention measures),Roche's anti -influenza drug Diffise's sales in 2010 were reduced compared with last year,The level has also declined significantly since 2009。The potential growth of Roche still exists,This is closely connected with it as a tumor monoclonal antibody (MAB)。

 

Astraikon's sales increased by 1.4%compared with last year,Indus of other Tingxin drugs continues to show a strong growth trend,Therefore, it is possible to position it as a Lipitor (Lipcao) inheritor。Recently in the fierce competition of hebin -like drugs to treat atherosclerosis,The data obtained failed to display Astraikon's products and Pfizer's leading products are more My stake betting appimportant,This increases stake betting appthe risks that Crestor (Ru Shuzanda) will face after the expiration of Lipcarian patents in November 2011。Johnson & Johnson's 2009-2010 annual performance is also affected by competition caused by generic drugs,It is mainly manifested as the special rights rights of Vesita (Lipidone) and Tyra (Topim)。

 

Other data also fully indicates,Pharmaceutical companies in the top 100 rankings occupy a high -density area for the entire industry income,These companies generate more than $ 10 billion of prescription drug sales,A total of 18 enterprises in sales are 460 billion US dollars,equivalent to 71%of Stake Sports BettingThe total sales of the top 100 pharmaceutical companies。These data are very important for the evaluation of defining the "large pharmaceutical company" team,It makes a large number of companies the focus of attention。The most important of which is the TEVA Pharmaceutical Company,It is the leading company of global generic drug companies。

 

Teva's rise in the past ten years has prompted the rapid transformation of the generic drug market and industry,The expiration of a series of popular patents and the increasingly paid attention to saving medical costs in the market stimulate their growth。TEVA hopes to get positive winning streak from a successful generic drug company,No controversy,Its ways of operation will change。The company has set a large goal,Leadership of the imitation drug market,Partial stimulation by acquisition,plus enhanced its product supply。Just like Sandoz,Teva also hopes to form a biotechnology drug market,This will be able to obtain huge commercial interests。

 

This team of 10 billion US dollars also has some cooperation with other large pharmaceutical companies,If AMGEN,Japanese Pharmaceutical Giant Takeda,ASTELLAS,Insulin -dependent Diabetes Expert Noe and Nord。Biopharmaceutical Company continues to operate strongly on the subject,Reduce the dependence of small molecular products,This is the main goal of an ambitious imitation industry。Gilead (Gilead) still performed outstandingly in its biopharmaceutical counterparts,Especially supported by the leading position in HIV/AIDS treatment market。Some ironic is,Gilead's HIV/AIDS's specialized rights include small molecular products,Its success in this field is largely derived from effective survival cycle management。

 

No doubt,From the ranking of the ranking,The top 100 pharmaceutical companies rank among the top European and American companies。In the first 25th place,Enterprises with sales of more than $ 5 billion,10 Come in the United States,9 are here in Europe,5 people come in Japan,1 house comes in other places (Sille in Israel)。On the basis of global,There is an interesting trend in Japanese companies,&A as a common means to achieve breakthroughs in the international market,Reduce dependence on domestic departments。

 

Top 100 Top 100 Rankings,Sales in 2010 reached a total of $ 649 billion,Compared with 596 billion US dollars in 2009, it increased by 8.9%,This indicates that the entire industry continues to expand strongly (although there is M&A help)。But,The opposite of this,Stake Sports BettingThe total sales of the top 10 companies have Stake Sports Bettingonly increased by 1.2%compared with last year,rose from US $ 3120 billion to 346 billion US dollars,This is two important M&A incident related (Pfizer acquired Wyeth and Merhado acquisition of Xianlingya)。

 

In addition,Only 3 companies with the top 10 companies in the sales performance of sales in 2009-2010 are mainly due to continuous growth: Nova、Lilly and Astrikan。Among these companies,Only Nuohua's growth rate to Stake Sports BettingThe total sales of the top 100 is comparable to (8.5%)。And Eli Lilly and Astrikon due to the invasion of popular generic drugs,In the next few years, it will face the problem of income growth and compression。

 

Although small and medium -sized enterprises face an increasingly challenging market environment,Large companies in the industry are forced to cooperate with the ambitious imitation drug industry,Competition of generic drugs,Especially the invasion of the sales of best -selling brands is still the main obstacle to the growth of sales in the top 100 rankings,This is also the reason for promoting 1.2%of the growth rate in the top 10 peers this year。

 

Large pharmaceutical companies manufacture the next generation of major products may not become an important challenge。Many vast disease markets with a huge population and the methods of unified treatment of patients with various diseases have been sold through the standard of generic drugs of gold standards。However, in these fields,Breakthrough drugs still have room for,Due to the return of high business in the imitation market,More opportunities will also have obvious limits。This leads to a change in areas that cannot basically meet the needs of patients,It is characterized by a large number of patients decrease,Support more funds effective treatment,This improves the current medical standards。

 

In short,,The industry leading companies are not only facing major invasion of the core income caused by the competition of generic drugs,It is also forced to fundamentally change their basic strategies,Pay attention to the growth mode far from the central focus。Converse,Compressed pharmaceutical companies will continue to tend to use M&A as a means to promote growth。But,Implementation of M in the past&A's decision is often promoted by global scale,At least part of the recent example is due to their diversification in different business areas,The focus of the disease,Emerging Market,Imitation or non -prescription medicine provided by consumers' health。

 

In addition,Due to imitation drug competition and other market challenges,M&A to increase the cost reduction of the acquisition company has become an increasingly common and feasible means。One of the advantages of large pharmaceutical companies away from traditional popular products is that it can reorganize important funds through relevant structure and infrastructure,Especially the cost of sales and markets。In this background of cutting costs,When encountering R & D investment,Leading companies face a balanced adjustment,This is customized in many cases,and when producing breakthrough Stake Sports Bettingproducts in the later production line,Related persons hope that the stake sports betting appinvestment here can gradually decrease。

 

Although Merhadon continues to follow Pfizer’s income method,In 2010, R & D investment is better than its competitors in the United States,As a result, the cost of acquisition of Xianlingya Merhadon's investment in R & D is almost doubled,reached $ 11 billion; Pfizer rose from $ 7.8 billion to $ 9.4 billion,This is largely because of the acquisition of Wyeth。The top 10 companies in the unified view,Many enterprises have risen steadily from last year,Except Sanofi、The investment of Johnson & Johnson and GlaxoSmith is lower than the level of 2009。Sanofi quotes the road to the development of the company's research and development of the company,The investment decreased by 553 million US dollars than last year,The company adheres to the concept of "quality instead of quantity",This trend will be more common in the top 100 rankings next year,Considering the announcement of many large pharmaceutical companies on cutting cost measures recently,Prove that the investment in research and development will no longer be "sacred"。

 

Witness 2009-2010 M&A's intense,In 2011, this activity was rarely seen。Despite the data indicating that M is in history&A's feelings have a soft spot and did not alleviate the damage caused by generic drugs,But the major transactions like Sanofi and Novartis,React M&A's long -term importance,It will definitely appear again in the future top 100 rankings。